Injectable Hydrogel Reduced Glioblastoma Recurrence in Mice
A new hydrogel treatment shows promise in preventing brain tumor growth by disrupting connections between neurons and cancer cells.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Do you believe current advances in cancer neuroscience will lead to effective new patient treatments?
In a 2026 study, researchers developed an injectable hydrogel designed to deliver targeted RNA therapies directly to the site of brain tumor removal. This strategy successfully reduced tumor recurrence and improved survival in mouse models of glioblastoma.
Why it matters
Glioma growth is often fueled by synaptic inputs from healthy neurons, a process that has historically been difficult to block without damaging normal brain function. This treatment offers a potential path to suppressing these tumor-promoting signals locally after surgery.
A preclinical study published in 2026 evaluated the HPAC-siNTRK2@Gel system in a mouse glioblastoma model. The treatment, which targets the BDNF receptor TrkB, demonstrated an ability to reduce tumor recurrence and enhance survival without impairing behavioral function in the subjects.
The players
Nature Biomedical Engineering
A monthly peer-reviewed scientific journal that publishes significant research in the field of biomedical engineering.
The details
The treatment uses a hydrogel injected locally at the site where a tumor has been surgically removed. By delivering small interfering RNA (siRNA) against Ntrk2, the hydrogel inhibits the BDNF receptor TrkB, effectively disrupting the synapses between neurons and cancer cells. This localized approach aims to starve the residual tumor cells of growth-promoting synaptic inputs while minimizing effects on healthy neurological function, further potentiating the benefits of standard chemoradiotherapy.
Timeline
2026: The research findings were published in the journal Nature Biomedical Engineering.
Health Landscape
This development situates itself within the evolving field of cancer neuroscience, which seeks to understand how malignant tumors hijack normal neural activity to drive their own growth. It represents a shift from conventional systemic approaches toward localized, synapse-targeted interventions.
This research remains in the early stages of preclinical development and is not currently available for patient care. It highlights an important area of study regarding how brain tumors interact with neural networks, which is a topic worth discussing with a neuro-oncologist during care planning.
The takeaway
Targeting the synaptic signals that tumors use to grow is a promising new frontier in brain cancer research. Patients and families can track the progress of these neuroscience-based therapies by following updates from major neuro-oncology research centers.
Further reading
For more information on the latest approaches to brain tumor treatment, explore the Cancer section.
More information
Read the full results in the Nature Biomedical Engineering research paper.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe current advances in cancer neuroscience will lead to effective new patient treatments?
